SonataPlus - a better way
Newport Beach, CA (PRWEB) April 06, 2016
Gregory DiRienzo, CEO of New Life Cancer Centers (http://www.newlifecancercenters.com) announces that a recently published study in the December 2015 issue of Journal of Liver Research, Disorders and Therapy reveals a patented, tumor-targeted, immune-chemo therapy has been shown to possibly shrink and even destroy pancreatic tumor(s) within weeks of commencing treatment for late stage pancreatic cancer.
According to internationally respected cancer researcher and clinical oncologist, Baofa Yu, M.D., results of the study could lead to fewer pancreatic patients requiring surgically invasive pancreatic tumor removal. The study went on to show that when slow released chemo drugs and select haptens are placed directly into the tumor, potential “anti-cancer vaccines” are set in motion, possibly deterring and/or hampering cancer metastasis. These same haptens have been shown to enhance patient-specific autologous tumor antigens known to induce self-vaccination like tumor-specific responses.
The concept of tumor-targeted drug delivery for various tumor types has been known for decades, with some examples showing clinical feasibility in the reduction of both toxicity and tumor growth, but not in pancreatic cancer patients. Pancreatic cancer is located in a crucial organ surrounded by vital tissues and organs such as the duodenum, gallbladder, portal vein, and aorta. Invasion of these organs by pancreatic cancer tumor(s) is very common and most often leads to an inoperative and/or unresectable situation.
Pancreatic cancer with a 6% five-year survival rate and median survival of 6-9 months, remains one of the most malignant and aggressive cancers in the world. It is the 4th leading cause of cancer death in the U.S.
Alan Morell, Creative Management Agency Appointment
New Life Cancer Centers has appointed Alan Morell, CEO, THE CREATIVE MANAGEMENT AGENCY: Creative Managment Partners, to develop New Life Cancer Center’s overall growth strategy and market positioning for global cancer patients sectors. The Agency is responsible for an overall marketing strategy, including identifying relevant cancer support associations for media campaigns. Mr. Morell coordinates with hundreds of news affiliates including Fox, MSNBC, and CNBC, among others. The client list ranges from select individuals in Literary; Broadcast; Sports, Entertainment, the Arts, to Global Corporations.
For Further Information:
(http://www.newlifecancercenters.com)
(http://www.newlifecancercenters.com/published-studies)
(http://www.progenacell.com)
(http://www.creativemanagementpartners.com)
NEW LIFE CANCER CENTERS
Newport Beach, CA
001.949.939.0050
info(at)newlifecancercenters(dot)com
SOURCE: NEW LIFE CANCER CENTERS
